Benitec Biopharma Announces Late Breaking Oral Abstract Presentation on BB-301 Phase 1b/2a Clinical Study at the 29th Annual Congress of the World Muscle Society
Benitec Biopharma Inc. (BNTC)
US:NASDAQ Investor Relations:
benitec.com/for-investors/investor-faqs
Company Research
Source: GlobeNewswire
HAYWARD, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that a Late Breaking Abstract on BB-301 was accepted for oral presentation at the 29th Annual Congress of the World Muscle Society, taking place in Prague, Czech Republic from October 8-12, 2024. The Late Breaking Abstract entitled “Interim Clinical Data Summary: A Phase 1b/2a Open-label, Dose Escalation Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of an AAV9-based gene therapy (BB-301) Administered to Subjects with Oculopharyngeal Muscular Dystrophy (OPMD) with Dysphagia” will be presented on October 12, 2024. Late Breaking Oral Presentation Title: Interim Clinical Data Summary: A Phase 1b/2a Open-label, Dose Escalation Study
Show less
Read more
Impact Snapshot
Event Time:
BNTC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BNTC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BNTC alerts
High impacting Benitec Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
BNTC
News
- Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational UpdateGlobeNewswire
- Benitec Biopharma CEO to Participate in OPMD Awareness Day WebinarGlobeNewswire
- Benitec Biopharma Inc. (NASDAQ: BNTC) is now covered by analysts at Guggenheim. They set a "buy" rating and a $17.00 price target on the stock.MarketBeat
- Benitec Biopharma Inc. (NASDAQ: BNTC) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.MarketBeat
- Benitec Biopharma Inc. (NASDAQ: BNTC) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $13.00 price target on the stock.MarketBeat
BNTC
Sec Filings
- 9/26/24 - Form 8-K
- 9/26/24 - Form 10-K
- 9/5/24 - Form 8-K
- BNTC's page on the SEC website